Home › Moberg Pharma announces successful results for MOB-015 in a Phase II...
 

Keywords :   


Moberg Pharma announces successful results for MOB-015 in a Phase II...

2014-09-17 10:42:21| Appliances - Topix.net

Moberg Pharma AB announces successful top-line results from a phase II study for MOB-015 in onychomycosis . The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.

Tags: results ii successful phase

Category:Consumer Goods and Services

Latest from this category

All news
30.06Tata offers to meet unions if strike called off
30.06Affordable home families hit by 450% gas price rise
30.06The big problem facing whoever wins the election
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Major UK high street banks say payment issues fixed
28.06More flights cancelled as Aer Lingus dispute continues
28.06Asda and Tesco face legal action over E. coli cases
Consumer Goods and Services »
30.06Tata offers to meet unions if strike called off
30.06Hurricane Beryl Public Advisory Number 8A
30.06Hurricane Beryl Graphics
30.06Eastern North Pacific Tropical Weather Outlook
30.06Atlantic Tropical Weather Outlook
30.06Hurricane Beryl Update Statement
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
More »